secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2024-08-27T23:59:59+00:00
Accession:  0001104659-24-093434
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics appoints Angus Russell to Board, Audit Committee
-----------------------------------------------------------------------

- Angus Russell appointed Class I director effective Aug 26, 2024; term expires at 2027 annual meeting.
- Russell joins Audit Committee; Ted Love, M.D. transitioned off the Audit Committee.
- Granted option for 75,000 ordinary shares (25,000 ADS) vesting over 36 months.
- Annual cash retainers: $45,000 for Board service plus $10,000 for Audit Committee, prorated for 2024.
- Board determined Russell independent under Nasdaq standards and meets audit committee requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465924093434/0001104659-24-093434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465924093434/tm2422732d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-093434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer